

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**THIRD QUARTER**  
**2007**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	3Q '07 vs. 3Q '06					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	-	814	-6%	301	4%	513
FOSAMAX	-6%	725	-5%	471	-8%	254
SINGULAIR	17%	1,018	14%	718	27%	300
ZOCOR	-41%	218	-64%	55	-26%	163
Vaccines:						
GARDASIL	*	418	*	328	*	91
ROTATEQ	*	171	*	161	*	10
ZOSTAVAX	*	61	*	61	N/A	-
OTHER VIRAL VACCINES <sup>(1)</sup>	73%	428	78%	412	2%	16
HEPATITIS VACCINES	-	68	4%	57	-18%	11
OTHER VACCINES	-1%	97	-4%	79	17%	18
Other Reported Products:						
AGGRASTAT	-5%	21	N/A	-	-5%	21
ARCOXIA	15%	76	N/A	-	15%	76
CANCIDAS	6%	135	-25%	34	24%	101
COSOPT / TRUSOPT	3%	197	-7%	86	13%	111
CRIXIVAN / STOCRIN	-13%	72	-28%	5	-12%	67
EMEND	20%	49	3%	33	84%	16
INVANZ	36%	50	22%	27	57%	23
JANUVIA	*	185	*	171	*	14
JANUMET	*	19	*	17	*	1
MAXALT	19%	125	22%	86	13%	39
PRIMAXIN	2%	186	-15%	47	10%	139
PROPECIA	12%	99	4%	38	17%	61
PROSCAR	-30%	90	-77%	8	-13%	82
TIMOPTIC / TIMOPTIC XE	-7%	28	-17%	2	-7%	27
VASOTEC / VASERETIC	-11%	119	N/A	-	-11%	119
ZOLINZA	*	3	*	3	N/A	-

\* 100% or over

N/A - Not Applicable

<sup>(1)</sup> - Includes ProQuad, M-M-R II and Varivax.

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	3Q '07	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES</b>	\$ 6,074	12%	9	1	2
U.S. (\$ MM)	3,767	16%	12	4	N/A
Foreign (\$ MM)	2,307	7%	5	-3	5

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**SEPTEMBER YEAR-TO-DATE**  
**2007**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	SEPTEMBER YTD '07 vs. SEPTEMBER YTD '06					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	7%	2,459	10%	907	5%	1,552
FOSAMAX	-4%	2,253	-	1,460	-10%	793
SINGULAIR	19%	3,112	16%	2,196	25%	916
ZOCOR	-73%	654	-93%	128	-24%	527
Vaccines:						
GARDASIL	*	1,141	*	925	*	216
ROTATEQ	*	375	*	357	*	18
ZOSTAVAX	*	151	*	151	N/A	-
OTHER VIRAL VACCINES <sup>(1)</sup>	73%	1,018	83%	966	-14%	52
HEPATITIS VACCINES	21%	219	28%	185	-5%	34
OTHER VACCINES	29%	285	21%	213	61%	72
Other Reported Products:						
AGGRASTAT	-4%	65	N/A	-	-4%	65
ARCOXIA	28%	245	N/A	-	28%	245
CANCIDAS	2%	403	-37%	107	31%	296
COSOPT / TRUSOPT	11%	575	12%	254	10%	321
CRIXIVAN / STOCRIN	-4%	230	-15%	16	-3%	214
EMEND	51%	144	37%	101	*	43
INVANZ	39%	137	29%	76	55%	62
JANUVIA	*	415	*	391	*	25
JANUMET	*	43	*	41	*	2
MAXALT	16%	341	19%	230	9%	112
PRIMAXIN	9%	568	3%	159	11%	410
PROPECIA	18%	293	5%	113	27%	179
PROSCAR	-34%	328	-75%	54	-2%	274
TIMOPTIC / TIMOPTIC XE	-6%	88	-13%	6	-6%	82
VASOTEC / VASERETIC	-10%	369	N/A	-	-10%	369
ZOLINZA	*	8	*	8	N/A	-

\* 100% or over

N/A - Not Applicable

<sup>(1)</sup> - Includes ProQuad, M-M-R II and Varivax.

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	SEP YTD '07	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES</b>	\$ 17,955	8%	6	=	2
U.S. (\$ MM)	10,969	9%	7	3	N/A
Foreign (\$ MM)	6,986	6%	5	-3	5

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**THIRD QUARTER**  
**2007**

**EQUITY INCOME FROM AFFILIATES (millions of dollars)**

	3Q `07	3Q `06	YTD 2007	YTD 2006
MERCK / SCHERING-PLOUGH	\$ (480.9)	\$ (350.1)	\$ (1,293.1)	\$ (858.1)
ASTRAZENECA LP	(181.2)	(173.7)	(608.3)	(602.6)
Other <sup>(1)</sup>	(106.4)	(71.6)	(278.8)	(249.5)
<b>TOTAL</b>	<b>\$ (768.5)</b>	<b>\$ (595.4)</b>	<b>\$ (2,180.2)</b>	<b>\$ (1,710.2)</b>

<sup>(1)</sup> Primarily reflects results for Merial Limited, and joint ventures with Sanofi Pasteur and Johnson & Johnson.

**JOINT VENTURE SALES DETAIL (millions of dollars)**

All sales reported here are end-market JV sales, presented on a "NET" basis.

<b>Merial</b>	3Q `07	3Q `06	YTD 2007	YTD 2006
IVOMEK, HEARTGARD, other avermectins	\$ 112.8	\$ 111.5	\$ 366.7	\$ 362.0
FRONTLINE	241.7	217.1	866.1	732.6
BIOLOGICALS	162.0	143.5	472.8	435.6
Other Animal Health	66.7	61.4	192.0	175.4
<b>TOTAL MERIAL SALES</b>	<b>\$ 583.2</b>	<b>\$ 533.5</b>	<b>\$ 1,897.6</b>	<b>\$ 1,705.6</b>

<b>Sanofi Pasteur-MSD</b>	3Q `07	3Q `06	YTD 2007	YTD 2006
HEPATITIS VACCINES	\$ 18.0	\$ 17.8	\$ 53.9	\$ 54.3
VIRAL VACCINES	20.7	24.9	65.0	69.6
Other Vaccines <sup>(1)</sup>	400.6	187.0	780.0	455.6
<b>TOTAL SANOFI PASTEUR-MSD SALES</b>	<b>\$ 439.3</b>	<b>\$ 229.7</b>	<b>\$ 898.9</b>	<b>\$ 579.5</b>

<sup>(1)</sup> Includes sales of *Gardasil* of \$137.0 million in 3Q07 and \$245.0 million for the first nine months of 2007.

<b>Merck / Schering-Plough Collaboration</b>	3Q `07	3Q `06	YTD 2007	YTD 2006
VYTORIN	\$ 693.0	\$ 526.6	\$ 2,003.2	\$ 1,402.4
ZETIA	607.0	501.9	1,728.5	1,392.7
<b>TOTAL MERCK / SCHERING-PLOUGH SALES</b>	<b>\$ 1,300.0</b>	<b>\$ 1,028.5</b>	<b>\$ 3,731.7</b>	<b>\$ 2,795.1</b>

**OTHER (INCOME) EXPENSE, NET (millions of dollars)**

	3Q `07	3Q `06	YTD 2007	YTD 2006
INTEREST INCOME	\$ (186.9)	\$ (195.0)	\$ (540.9)	\$ (564.6)
INTEREST EXPENSE	91.5	87.7	297.2	277.8
EXCHANGE GAINS	(8.3)	(11.5)	(39.8)	(4.5)
MINORITY INTERESTS	30.6	30.7	92.0	90.7
Other, net	(107.8)	(46.6)	(329.7)	(104.8)
<b>TOTAL</b>	<b>\$ (180.9)</b>	<b>\$ (134.7)</b>	<b>\$ (521.2)</b>	<b>\$ (305.4)</b>